# Seagen Inc. – Consensus ‘hold’ rating and 9.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/seagen-inc.consensus-hold-rating-and-9.0-upside-potential/4121126226
- Published: 2023-08-30T12:04:30+01:00
- Author: Charlotte Edwards

**Seagen Inc.** which can be found using ticker (SGEN) now have 12 market analysts
covering the stock. The analyst consensus now points to a rating of ‘hold’. The 
target price High/Low ranges between 229 and 180 and has a mean target at $224.83.
Now with the previous closing price of $206.26 this would indicate that there is
a potential upside of 9.0%. The 50 day MA is $195.18 and the 200 moving average 
now moves to $173.49. The company has a market cap of 38.85B. The current share 
price for the company is: 206.96 USD

 The potential market cap would be $42,343,361,944 based on the market consensus.

The company has a dividend yield of 5.95%. Other points of data to note are a P/
E ratio of -, revenue per share of 11.6 and a -12.56% return on assets.

Seagen Inc. is a biotechnology company that develops and commercializes targeted
therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or
brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV,
or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers;
TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth
factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or
tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers.
It is also advancing a pipeline of novel therapies for solid tumors and blood-related
cancers designed to address unmet medical needs and improve treatment outcomes for
patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s
antibody-drug conjugate (ADC) technology that utilizes the targeting ability of 
monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

Share on: